NEO
Neogenomics Inc.

2,843
Mkt Cap
$1.56B
Volume
1.4M
52W High
$19.12
52W Low
$4.72
PE Ratio
-13.65
NEO Fundamentals
Price
$12.12
Prev Close
$12.07
Open
$12.06
50D MA
$10.04
Beta
1.42
Avg. Volume
2.32M
EPS (Annual)
-$0.6216
P/B
1.86
Rev/Employee
$300,257.27
Loading...
Loading...
News
all
press releases
NeoGenomics, Inc. $NEO Shares Bought by Samjo Management LLC
Samjo Management LLC grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 11.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
American Century Companies Inc. Has $25.71 Million Stock Position in NeoGenomics, Inc. $NEO
American Century Companies Inc. raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 6.0% during the 2nd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
Insider Selling: NeoGenomics (NASDAQ:NEO) EVP Sells 20,916 Shares of Stock
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) EVP Alicia Olivo sold 20,916 shares of the company's stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of...
MarketBeat·5d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Takes Position in NeoGenomics, Inc. $NEO
Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 2nd quarter, according to the company in its most recent...
MarketBeat·14d ago
News Placeholder
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Hold" from Analysts
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has earned a consensus recommendation of "Hold" from the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. One...
MarketBeat·18d ago
News Placeholder
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB...
Business Wire·1mo ago
News Placeholder
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of +50.00% and +2.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
NeoGenomics Reports Third Quarter 2025 Results
NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended...
Business Wire·1mo ago
News Placeholder
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1mo ago
News Placeholder
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·2mo ago

Latest NEO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.